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Background: α-Dystroglycan (α-DG) is heavily glycosylated within its central mucin-like domain. The glycosylation
shell of α-dystroglycan is known to largely influence its functional properties toward extracellular ligands. The
structural features of this α-dystroglycan domain have been poorly studied so far. For the first time, we have
attempted a recombinant expression approach in E. coli cells, in order to analyze by biochemical and biophysical
techniques this important domain of the α-dystroglycan core protein.
Results: We expressed the recombinant mucin-like domain of human α-dystroglycan in E. coli cells, and purified it
as a soluble peptide of 174 aa. A cleavage event, that progressively emerges under repeated cycles of freeze/thaw,
occurs at the carboxy side of Arg461, liberating a 151 aa fragment as revealed by mass spectrometry analysis. The
mucin-like peptide lacks any particular fold, as confirmed by its hydrodynamic properties and its fluorescence
behavior under guanidine hydrochloride denaturation. Dynamic light scattering has been used to demonstrate that
this mucin-like peptide is arranged in a conformation that is prone to aggregation at room temperature, with a
melting temperature of ~40°C, which indicates a pronounced instability. Such a conclusion has been corroborated
by trypsin limited proteolysis, upon which the protein has been fully degraded in less than 60 min.
Conclusions: Our analysis indirectly confirms the idea that the mucin-like domain of α-dystroglycan needs to be
extensively glycosylated in order to reach a stable conformation. The absence/reduction of glycosylation by itself
may greatly reduce the stability of the dystroglycan complex. Although an altered pattern of α-dystroglycan
O-mannosylation, that is not significantly changing its overall glycosylation fraction, represents the primary
molecular clue behind currently known dystroglycanopathies, it cannot be ruled out that still unidentified forms of
αDG-related dystrophy might originate by a more substantial reduction of α-dystroglycan glycosylation and by its
consequent destabilization.
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α-Dystroglycan (DG) is the peripheral subunit of the DG
complex that lies at the basement membrane/sarco-
lemma cellular crossroad and that is important for
muscle fibers’ stability. α-DG glycosylation pattern is
considered crucial for its function in terms of laminin
binding affinity, and a disruption of the α-DG/laminin
network is at the basis of a group of diseases spanning* Correspondence: andrea.brancaccio@icrm.cnr.it
†Equal contributors
2Istituto di Chimica del Riconoscimento Molecolare (CNR) c/o Istituto di
Biochimica e Biochimica Clinica, Università Cattolica del Sacro Cuore, Largo
F. Vito 1, Roma, 00168, Italy
Full list of author information is available at the end of the article
© 2013 Bozzi et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orfrom the severe congenital to the much milder limb-
girdle muscular dystrophies, defined as secondary
dystroglycanopathies [1].
The DG complex is composed of two subunits (α and β)
that are liberated upon an early processing step of a
unique precursor of 895 aa in humans (pre-DG), that is
thought to take place within the endoplasmic reticulum
right after translation. The α-DG is an extracellular
protein, highly and heterogenously glycosylated, whilst
the β-DG subunit is transmembrane. A biochemical
analysis of the α-DG subunit reveals a structural
organization characterized by two terminal globular
portions separated by an elongated central section
(mucin-like) [2]. Although a few glycosylation sites havetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Purification of the recombinant α-DG mucin-like
domain, α-DG(316–484). α-DG-DG(316–484) purification steps were
analysed by 12% SDS-PAGE stained with Coomassie Brilliant Blue R-250
dye. Lane 1, overall cell lysate from E. coli expressing the chimaeric
protein Trx-α-DG(316–484); lane 2, purified Trx-α-DG(316–484); lane 3,
Trx-α-DG(316–484) upon thrombin cleavage: two upper bands
referring to α-DG peptides plus a lower band of Trx are observable;
lane 4, purified and concentrated α-DG(316–484). The lower band
refers to a processed α-DG(316–461) product that has been
characterized by mass spectrometry.
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domains of α-DG, most of the O-linked oligasaccharidic
chains protrude from Thr and Ser residues placed within
the central mucin-like domain [3].
The whole maturation process of α-DG is known to
be highly regulated and to take place in the typical sub-
cellular locations, where multiple enzymes are required
for the post-translational modification of the α-DG core
protein [4]. An ever growing list of acclaimed, putative or
uncharacterized glycosyltransferases (see [5] and refer-
ences therein) is thought to be involved in the decoration
of α-DG along the endoplasmic reticulum and the Golgi
apparatus. It is quite unlikely that α-DG would represent
the unique target of such a large number of enzymes
[6]. Nevertheless, a long list of nonsense or missense
mutations affecting these enzymes seems to lead to
muscular dystrophy phenotypes whose major molecular
trait is believed to be a reduction of α-DG functionality,
depending on the alteration of its glycosylation shell.
The general concept is that a hypoglycosylated α-DG
would be less active in binding laminin-2, or other matrix
binding partners, thus provoking a reduction of the
overall stability of the sarcolemma preceding the onset of
inflammation, fibrosis and necrosis typical of many
severe muscular dystrophies.
On such premise, it is rather clear that the mucin-like
central section of α-DG represents its most interesting
functional hot spot. Recently, several works have
highlighted specific Thr (and Ser) residues as glycosyla-
tion sites and/or identified the structure of the modify-
ing saccharides [7-12]. However, three-dimensional
structures referring to this specific domain of α-DG
alone or in complex with laminin or other ligands are
not available yet.
An approach that has been particularly successful in
our lab for the study of the subdomain organization of
α- and β-DG subunits, is represented by the expression
of unmodified recombinant peptides spanning portions
or isolated subdomains of both the DG subunits [1].
Therefore, we have attempted a similar approach for the
study of the mucin-like portion of α-DG. We have been
able to obtain reasonable amounts of a recombinant
protein spanning the entire mucin-like portion of human
α-DG in a soluble fashion, and we have characterized its
conformation with a series of biophysical techniques.
Such recombinant peptide may be useful and pave the
way for further biochemical and biotechnological studies
on this important domain of α-DG.
Results and discussion
The mucin-like domain cannot be quantitatively obtained
in a glycosylated fashion from eukaryotic cells and there-
fore we decided to apply our E. coli-based recombinant
approach already used for the expression and purificationof other DG domains [1,13]. The primary structure of the
portion of human α-DG under analysis, including the
Arg-Val site that we have found to be sensitive to prote-
ases (see below), is reported in Additional file 1: Table S1.
Samples collected after each step of the expression
and purification protocol were separated by SDS-PAGE
(Figure 1). It is noteworthy that the electrophoretic mobil-
ity of the purified mucin-like domain, α-DG(316–484), is
much lower than expected on the basis of its molecular
mass as reported for natively unfolded proteins [14].
The protein yield is good (circa 5 mg/l of culture), and
the full-length protein is relatively stable, since it can be
submitted to thrombin digestion and retrieved in a
thioredoxin-free form. In addition, the protein remains
soluble during all the purification steps. Nevertheless, it
is evident a C-terminal processing event (see the lower
band in lanes 2 and 4 of Figure 1) that is likely to take
place within the E. coli cells, and that we have also
observed after repeated cycles of freezing and thawing
(data not shown).
In order to further characterize the two protein bands
observed in SDS-PAGE, we have employed Capillary
Electrophoresis analytical techniques coupled with ESI
(electrospray ionization)-ion trap mass spectrometry
detection (CE-ESI-IT-MS). The Total Ion Current (TIC)
CE-MS profile of the purified α-DG mucin-like domain,
α-DG(316–484), is characterized by an intense wide
peak in a migration window within a 10.5-11.2 min time
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(panel I). The deconvolution of the ESI mass spectrum
registered between 10.5 and 11.2 min (panel III) revealed
the presence of two protein species in the main peak,
corresponding to the full-length α-DG(316–484) (theor-
etical mw 18252 Da) and to its truncated form devoid of
the C-terminal fragment (theoretical mw 15470 Da),
confirming the occurrence of a proteolytic cleavage. To
prevent possible degradation due to dilution, a very con-
centrated sample was analyzed, which produced the loss
of resolution power that usually characterizes CE separa-
tions. The analysis of the ESI mass spectrum registered
between 9.8 and 10.5 min (small front peak A 2529.6)
also enabled identification of the shed C-terminal frag-
ment (theoretical mw 2529.9 Da). The panel II in Figure 2
shows the relative deconvoluted ESI mass spectrum.
To evaluate the stability of the mucin-like peptide, we
have analyzed its behavior by dynamic light scattering
(DLS) as a function of temperature. In Table 1, the Z-
average (referring to the particle diameter) and polydis-
persity index (PdI), a measure of the distribution of the
molecular masses, as well as the corresponding peak
size, intensity (%) and mass (%) values are reported; the
intensity peak distribution is also shown in Figure 3A.
The experimental diameter of the full length α-DG
(316–484), associated to the lower peak size (9 ± 3 nm),
was similar to the theoretical one, calculated on theFigure 2 Capillary electrophoresis-mass spectrometry (CE-MS) experim
recombinant mucin-like domain, α-DG(316–484), obtained by CE-ESI-IT-MS
(panel III) and in its front part (panel II) with their relative deconvolution arbasis of its molecular weight (18 kDa). The presence of
aggregates, represented by the higher peak of Figure 3A,
accounts for only 1% of the total mass contribution to
the scattered light of the protein solution.
The protein melting point is defined as the
temperature at which the protein is fully denatured. The
change in size that accompanies the protein denatur-
ation is identified using DLS techniques. Figure 3B
shows the temperature dependent Z-average diameter
and scattered intensity of α-DG(316–484) in phosphate
buffered saline (PBS). Although α-DG(316–484) lacks
secondary structure elements, as estimated by submit-
ting its primary structure to several different softwares
available for secondary structure prediction (data not
shown), the observation that the Z-average diameter and
scattering intensity values remain constant at tempera-
tures lower than 40°C suggests the presence of a defined
conformation of the protein; above this temperature the
mean dimension of the protein increases exponentially,
thus indicating the formation of denatured aggregates.
The fluorescence emission at 280 nm and the absorb-
ance spectra of α-DG(316–484) are reported in Figure 4A
and B. Lacking tryptophan and phenylalanine residues,
the intensities measured were those of the single tyrosine
residue in position 410 (see Additional file 1: Table S1),
with an absorbance and fluorescence maximum at 274
and 307 nm, respectively.ents. Total Ion Current (TIC) plot of the purified fraction of human
analysis (panel I). The average MS spectra recorded in the main peak
e also shown.
Table 1 Dynamic light scattering of the recombinant
mucin-like domain of human α-dystroglycan
Mode ± SD (nm) PdI (%) Intensity (%) Mass (%)
Z-average 111 ± 62 56 - -
Peak 1 9 ± 3 28 5 99
Peak 2 142 ± 78 48 95 1
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(316–484) as a function of guanidine hydrochloride con-
centration is reported in Figure 4C. The protein shows an
early decrease of fluorescence intensity upon unfolding,
and the process seems to be already concluded at low
guanidine concentration (1 M), thus confirming the un-
stable nature of the domain.
Overall, both DLS and the observed fluorescence be-
havior are in line with the idea that the recombinant
mucin-like domain still possesses some sort of defined
conformation at room temperature, although displaying
a low stability as such conformation can be rapidly lost
when increasing the temperature and/or the chaotropic
agent concentration.
Moreover, the reduced stability of the mucin-like pep-
tide has been also confirmed by limited proteolysis at
room temperature. Trypsin-based limited proteolysis of
the mucin-like domain completely disrupts the protein
in one hour (Figure 5), in a fashion that is reminiscent
of what we have observed for the natively unfolded N-
terminal β-DG domain [15]. It should be noted that typ-
ically stable proteins, including the C-terminal domain
of α-dystroglycan, are resistant to limited proteolysis for
up to 3 hours or longer [15].
Conclusions
The data reported in this paper show that the recombin-
ant mucin-like domain of α-DG, which we have produced
in a non-glycosylated form, although quite unstable can
be expressed and purified in reasonable amounts. Our re-
sults seem to be in line with what previously observedFigure 3 Dynamic light scattering. A) Intensity peak distribution and B)
α-DG(316–484) as function of temperature in PBS, pH 7.4. The arrow indicawith ovine submaxillary mucin, in which the apomucin
form collapses from an extended conformation when O-
GalNAc O-glycosylation is removed [16].
Although our unglycosylated mucin-like peptide is
clearly different from hypoglycosylated α-DG found in
patients, may our results add some new insight into the
current molecular view of dystroglycanopathies?
In muscles affected by dystroglycanopathies, α-DG
is still localized at the sarcolemma, due to the non-
covalent and sugar-independent interaction with the
β-subunit [17,18]. The current molecular view of
dystroglycanopathies implies that the observed reduc-
tion in sarcolemma stability would originate from the
reduction of the binding affinity displayed by α-DG to-
wards laminin, an event whose molecular basis is rep-
resented by an alteration of the O-mannosylated α-DG
moieties and not by its dramatic hypoglycosylation. In
addition, no evidence have been collected so far on
the fact that the hypoglycosylated α-DG isoform(s)
found in patients affected by dystroglycanopathies
would be significantly destabilized and therefore ex-
posed to preferential proteolysis. Of course, studies
aiming at the analysis of the biochemical characteris-
tics and stability of these hypoglycosylated α-DG mol-
ecules are warranted in order to further clarify this
interesting point.
However, surely an extreme, but fascinating, view
emerging from the data herein reported, is that α-DG
glycosylation would be required primarily for stabilizing
the conformation of its mucin-like domain (and confer-
ring resistance to proteases like metalloproteases or
others), as also proposed by Tran and colleagues [11],
and secondarily for laminin binding. Although in the
dystroglycanopathies currently known it is more common
to observe a reduction of some specific O-Man (important
for laminin binding) rather than of O-GalNAc (typical of
the mucin-like portion) glycans, it is not unreasonable to
foresee still unidentified cases of dystroglycanopathy in
which a scenario would emerge of a significantly reducedZ-Average diameter (solid line) and scattered intensity (dotted line) of
tes the measured melting point.
Figure 4 Fluorescence and absorption spectra. A) Fluorescence emission (Exλ = 280 nm) and B) absorbance spectra of α-DG(316–484) in PBS,
pH 7.4. C) Effect of raising concentrations of guanidine hydrochloride on the fluorescence intensity of α-DG(316–484).
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the hypoglycosylated α-DG molecule.
Interestingly, 20 years ago protease inhibitors (Bestatin
and Loxistatin) were already tested in Japan for their po-
tential beneficial effect on Duchenne mice (mdx) and pa-
tients with some encouraging results [19]. A similar action
has been recently observed using Batimastat (BB-94) [20].
Perhaps, in the future these drugs might be also tried
more specifically on mouse models or patients affected by
dystroglycanopathies, although a dangerous undesired
effect of these protease inhibitors could be to inhibit
the furin-driven proteolysis of the N-terminal domain of
α-DG that seems to represent a necessary step along its
maturation pathway [21].
Last but not least, from an exquisitely experimental
point of view, our novel recombinant peptide may rep-
resent an interesting target to be employed to testFigure 5 Limited proteolysis of the recombinant α-DG mucin-
like domain, α-DG(316–484). Limited proteolysis of the α-DG(316–
484) peptide (~5-10 μM) was carried out with 20 nM trypsin in PBS,
pH 7.4 at room temperature. Aliquots of the reaction mix were
collected at increasing times and analyzed by SDS-PAGE. Before
incubation with trypsin (t 0), α-DG(316–484) already displays two
bands corresponding to the entire peptide, α-DG(316–484), and to
the slightly smaller truncated peptide α-DG(316–461), characterized
by CE-ESI MS and originated via a C-terminal breakdown event.
Noteworthy, the electrophoretic mobility of the whole α-DG(316–
484) is much lower than expected on the basis of its molecular mass
(18252 Da). Trypsin digests both the peptides producing one lower
band at about 18 kDa (arrow), which is further fragmented, and
completely degrades them in about 1 h.in vitro the enzymatic action of POMT1 and POMT2,




cDNA of human DG, cloned in the retroviral expression
vector pBMN-IRES-PURO [24], was used as a template to
generate by PCR the DNA construct corresponding to the
mucin-like domain of α-DG, α-DG(316-484). Appropriate
primers were used to amplify the DNA sequence of inter-
est: forward 5′-CCCGTCGACGCTACACCCACACCTG
TCACTGCC-3′ and reverse 5′-CCCGAATTCTTAGGT
GGTGGTGCGAATACGAGTAGG-3′ SalI and EcoRI re-
striction sites are in bold type.
Protein expression and purification
The DNA construct obtained was purified and cloned into
a bacterial vector appropriate to express the protein as a
thioredoxin fusion product, also containing an N-terminal
6His tag and a thrombin cleavage site. The recombinant
fusion protein was expressed in E. coli BL21(DE3) Codon
Plus RIL cells and purified by affinity chromatography
using a Ni-NTA resin (Novagen, USA). About 25 mg of
thioredoxin fusion protein, previously dialyzed in a buffer
containing 20 mM Tris–HCl, 0.15 M NaCl, 2.5 mM
CaCl2, pH 8.4, were incubated with 8 NHI units of throm-
bin from human plasma (Sigma-Aldrich, USA) for 4 h at
room temperature, in order to separate the mucin-like
domain from its thioredoxin fusion partner. A second Ni-
NTA affinity chromatography step was carried out to
remove the thioredoxin fusion partner; the purity of the
isolated mucin-like domain was checked by 12% SDS-
PAGE. Protein staining in the polyacrylamide gel was
performed with Coomassie Brilliant Blue R-250 dye.
Limited proteolysis
Limited proteolysis of the mucin-like domain (~5-10 μM)
was carried out with 20 nM trypsin in PBS, pH 7.4 at room
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0, 5, 30, 60 and 180 min, and analyzed by 12% SDS-PAGE.
Capillary Electrophoresis-mass spectrometry (CE-MS)
experiments
The organic solvents used for CE-MS analysis were of
LC-MS grade. Methanol, trifluoroacetic acid (TFA)
(HPLC) and formic acid (98%) were from Mallinckrodt
Baker B.V. (Deventer, The Netherlands). Ultra pure
water was obtained from P.Nix Power System apparatus
(Human, Seoul, Korea). Sodium hydroxide pellets, pro
analysis, was from Merck (Darmstadt, Germany).
Capillary Electrophoresis experiments were performed on
an Agilent Technologies (Waldbronn, Germany) automated
apparatus, equipped with UV-diode array detector and
external nitrogen pressure, and coupled to an Esquire 3000
plus mass spectrometer (Bruker Daltonics, Bremen,
Germany) via a coaxial sheath liquid electrospray ion-
ization (ESI) interface (Agilent Technologies, Waldbronn,
Germany). The sheath liquid was composed by a mixture
of water/methanol (30:70, v/v) containing 0.1% of formic
acid (final content) and delivered by an external syringe
pump (Cole Palmer, Vernon Hills, Illinois, USA) at a
constant flow rate of 180 μl/h. Nebulising and drying gas
(nitrogen) were set at 10 psi and 4 l/min, respectively. The
nebulizer was set at 6 psi during sample injection process.
The dry gas temperature was 250°C. The mass spectrom-
etry capillary voltage was 4000 V. Mass spectrometry detec-
tion in ESI positive ionization was performed in full scan
mode of acquisition using a 500–1500 m/z scan range, with
a maximum accumulation time of 200 ms and upon acti-
vating the ICC instrumental function. Smart Parameters
Setting (SPS) was set at 800 m/z of target mass value.
Deconvolution of averaged ESI mass spectra was performed
by MagTran 1.0 software.
Separations were performed using 1.0 M formic acid
aqueous solution as background electrolyte (BGE) and a
50 μm I.D., 375 μm O.D. fused silica uncoated capillary
(Composite Metal Services, Hallow, Worcs., UK) of total
length of 85 cm. Effective lengths were 21.5 and 87 cm for
the UV and MS detection, respectively. The temperature of
the CE-MS assembly cartridge was 25°C and the applied CE
running voltage 26 kV (positive polarity mode). Samples
were injected at the anodic end of the capillary at 50 mbar ×
10 sec followed by BGE injection at 50 mbar × 15 sec.
The sample was thawed at room temperature and
immediately injected into the CE-MS apparatus after
dilution 1:2 (v/v) in a TFA aqueous solution 0.1% (v/v).
Dynamic light scattering
Dynamic light scattering (DLS) measurements on α-DG
(316–484) protein solutions were carried out with a
Zetasizer Nano S (Malvern Instruments, Malvern, U.K.)
equipped with a 4 mW He-Ne laser (633 nm).Measurements were performed at 25.0 ± 0.1°C, at an angle
of 173° from the incident beam. The sample was manually
injected into a 3 mm path length Suprasil quartz cuvette
(45 μl) (Hellma Italia, Milan, Italy); measurements were
always performed after automatic instrument optical align-
ment and data collected for at least 15 minutes after
injection. Each measurement consists of a subset of
runs automatically determined, each being averaged for
10 seconds. The Z-average diameter, directly referring to
the particle size, and the polydispersity index (PdI) were
obtained from a Cumulants analysis of the measured inten-
sity autocorrelation function, using version 6.32 of the
Nano software. Measured size, intensity and mass distribu-
tion were also collected. Finally, the protein melting point
was obtained measuring the temperature dependence of
the Z-average diameter and scattering intensity of the
protein solution, collecting data with a 2°C increment
temperature ramp and 3 minute equilibrium time from
25 to 90°C.
Fluorescence and absorbance studies
Fluorescence emission (Exλ = 280 nm) and absorbance
spectra were recorded at 25°C in a 3 mm quartz cell, on
samples dissolved in 100 mM PBS, pH 7.4 using a Spex
(Edison, NJ, USA) FluoroMax spectrofluorimeter and a DU
Series 700 UV/Vis spectrophotometer (Beckman Coulter,
Fullerton, CA), respectively. In order to test the chemical
stability of the α-DG(316–484) domain to unfolding,
fluorescence spectra were recorded as a function of
guanidine hydrochloride concentration as described else-
where [25,26]. After each addition of denaturing agent,
10 min were allowed for the solution to reach equilibrium
before spectra acquisition.
Additional file
Additional file 1: Table S1. Primary structure of the recombinant
mucin-like domain of human α-dystroglycan.
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